Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SH-DS01 + metronidazole appears to be a combination therapy that includes metronidazole (an antibiotic) and SH-DS01 (likely a probiotic). The search results mention this combination being studied in women with unexplained infertility who are seeking IVF treatment[1]. ## Metronidazole Component Metronidazole is a well-established nitroimidazole antimicrobial that treats infections caused by bacteria and protozoa. It works by killing bacteria or other organisms causing infections[6]. It's commonly used for: - Trichomoniasis (except during first trimester of pregnancy)[2] - Bacterial vaginosis[2] - Amebiasis[2] - Various anaerobic infections (skin, abdomen, heart, reproductive organs, CNS, respiratory system)[2] - Infections by Bacteroides species, Clostridium, Fusobacterium, Peptococcus and Peptostreptococcus[2] - Topically for inflammatory lesions of rosacea[2] Metronidazole is available in various formulations including oral tablets, intravenous infusion, and topical applications. ## SH-DS01 Component The search results don't provide specific information about SH-DS01, but based on context, it appears to be a probiotic formulation being studied alongside metronidazole. The combination is being investigated in a clinical trial for women with unexplained infertility who are seeking IVF treatment[1]. ## Important Interactions and Precautions When using metronidazole (which is part of this combination): - Do not take with disulfiram within two weeks[6][7] - Avoid alcohol consumption during treatment and for 3 days after (can cause disulfiram-like reactions)[3][4] - Monitor carefully if taking with: - Warfarin or other blood thinners (increased bleeding risk)[3][6] - Lithium (potential toxicity)[3][6] - Busulfan (may require dose adjustments)[6] - Phenytoin or phenobarbital (may reduce metronidazole effectiveness)[6][8] The specific dosing, complete safety profile, and efficacy of the SH-DS01 + metronidazole combination would depend on the particular clinical context and study protocols being used.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SH-DS01 + Metronidazole.